Evidence map›Paper›PMID 37566081›Full record

ArticleCells2023

Complement Dysregulation in Obese Versus Nonobese Polycystic Ovary Syndrome Patients.

Alexandra E Butler, Abu Saleh Md Moin, Thozhukat Sathyapalan, Stephen L Atkin

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Polycystic ovary syndrome as a metabolic disease.Nature reviews. Endocrinology · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Alexandra E ButlerRoyal College of Surgeons in Ireland Bahrain, Busaiteen P.O. Box 15503, Adliya, Bahrain.
Abu Saleh Md MoinRoyal College of Surgeons in Ireland Bahrain, Busaiteen P.O. Box 15503, Adliya, Bahrain.
Thozhukat SathyapalanAcademic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU6 7RU, UK.ORCID 0000-0003-3544-2231
Stephen L AtkinRoyal College of Surgeons in Ireland Bahrain, Busaiteen P.O. Box 15503, Adliya, Bahrain.ORCID 0000-0002-5887-7257
Royal College of Surgeons in Ireland - Bahrain · BHHull York Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUpregulation of complement system factors are reported to be increased in polycystic ovary syndrome (PCOS) and may be due to obesity and insulin resistance rather than inherently due to PCOS. We directly compared complement factors from an obese, insulin-resistant PCOS population to a nonobese, non-insulin-resistant PCOS population in a proteomic analysis to investigate this.

methodsPlasma was collected from 234 women (137 with PCOS and 97 controls) from a biobank cohort and compared to a nonobese, non-insulin-resistant population (24 with PCOS and 24 controls). Slow off-rate modified aptamer (SOMA) scan plasma protein measurement was undertaken for the following complement system proteins: C1q, C1r, C2, C3, C3a, iC3b, C3b, C3d, C3adesArg, C4, C4a, C4b, C5, C5a, C5b-6 complex, C8, properdin, factor B, factor D, factor H, factor I, Mannose-binding protein C (MBL), complement decay-accelerating factor (DAF) and complement factor H-related protein 5 (CFHR5).

resultsThe alternative pathway of the complement system was overexpressed in both obese and nonobese PCOS, with increased C3 (

conclusionThe upregulation of the alternative complement pathway was seen in nonobese PCOS and was further exacerbated in obese PCOS, indicating that this is an inherent feature of the pathophysiology of PCOS that is worsened by obesity and is reflected in the differences between the nonobese and obese PCOS phenotypes. However, the increase in the complement proteins associated with activation was counterbalanced by upregulation of complement inhibitors; this was evident in both PCOS groups, suggesting that insults, such as a cardiovascular event or infection, that cause activation of complement pathways may be amplified in PCOS.

Indexed as

Complement System ProteinsObesityPolycystic Ovary SyndromeAdultCase-Control StudiesFemaleHumansInsulin ResistanceYoung AdultComplement System ProteinsC3complement factorsfactor Bfactor Hpolycystic ovary syndromeproperdin

Identifiers

PMID37566081
PMCPMC10416938
OpenAlexW4385576330

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.